Roflumilast does not decrease COPD exacerbations in adequately treated patients, but subgroup analysis allows for shared decision making
2019 ◽
Vol 5
(1)
◽
Keyword(s):
<p>A critical appraisal and clinical application of Martinez FJ, Rabe KF, Sethi S, et al. Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting beta2-Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE(2)SPOND). A Randomized Clinical Trial. <em>Am J Respir Crit Care Med</em>. Sep 1 2016;194(5):559-567. doi: <a href="https://doi.org/10.1164/rccm.201607-1349OC">10.1164/rccm.201607-1349OC</a>.</p>
2017 ◽
Vol 37
(4)
◽
pp. 447-455
◽
2019 ◽
Vol 13
(11)
◽
pp. 1087-1094
◽